Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Works by Hompesch, Marcus
Results: 48
1
2
Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
3
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.
- Published in:
- 2016
- By:
- Publication type:
- journal article
4
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes.
- Published in:
- Diabetes Care, 2013, v. 36, n. 10, p. 3169, doi. 10.2337/dc13-0387
- By:
- Publication type:
- Article
5
Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?
- Published in:
- Pharmaceutical Medicine, 2014, v. 28, n. 3, p. 109, doi. 10.1007/s40290-014-0053-7
- By:
- Publication type:
- Article
6
Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes.
- Published in:
- 2019
- By:
- Publication type:
- journal article
7
Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
8
Targeting Hyperglycaemia with Anti-Obesity Drugs: Time for a Paradigm Shift?
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
9
Developing New Drugs for Diabetes and Cardiometabolic Disorders.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
10
Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase.
- Published in:
- Diabetes Care, 2013, v. 36, n. 2, p. 273, doi. 10.2337/dc12-0808
- By:
- Publication type:
- Article
11
Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects.
- Published in:
- 2011
- By:
- Publication type:
- journal article
12
Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects.
- Published in:
- Diabetes Care, 2011, v. 34, n. 12, p. 2496, doi. 10.2337/dc11-0721
- By:
- Publication type:
- Article
13
Accelerated Insulin Pharmacokinetics and Improved Postprandial Glycemic Control in Patients With Type 1 Diabetes After Coadministration of Prandial Insulins With Hyaluronidase.
- Published in:
- Diabetes Care, 2011, v. 34, n. 3, p. 666, doi. 10.2337/dc10-1892
- By:
- Publication type:
- Article
14
Availability of Inhaled Insulin Promotes Greater Perceived Acceptance of Insulin Therapy in Patients With Type 2 Diabetes.
- Published in:
- Diabetes Care, 2005, v. 28, n. 2, p. 427, doi. 10.2337/diacare.28.2.427
- By:
- Publication type:
- Article
15
α-Lipoic Acid in NIDDM Patients With Cardiac Autonomic Neuropathy.
- Published in:
- Diabetes Care, 1997, v. 20, n. 12, p. 1918, doi. 10.2337/diacare.20.12.1918a
- By:
- Publication type:
- Article
16
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
- Published in:
- BMC Pharmacology & Toxicology, 2013, v. 14, n. 1, p. 1, doi. 10.1186/2050-6511-14-26
- By:
- Publication type:
- Article
17
Exploring the insulin secretory properties of the PGD<sub>2</sub>-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients.
- Published in:
- PLoS ONE, 2018, v. 13, n. 12, p. 1, doi. 10.1371/journal.pone.0208998
- By:
- Publication type:
- Article
18
Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2020, v. 105, n. 4, p. e1235, doi. 10.1210/clinem/dgz258
- By:
- Publication type:
- Article
19
Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
- Published in:
- 2019
- By:
- Publication type:
- journal article
20
766-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, and Pharmacokinetics (PK) from Part 1 of a Phase 1b Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HV).
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-766-P
- By:
- Publication type:
- Article
21
765-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) from Part 2 of a Phase 1b Multiple Ascending Dose (MAD) Study in Patients with Type 2 Diabetes Mellitus (T2DM).
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-765-P
- By:
- Publication type:
- Article
22
901-P: Evaluation of the Analytical Performance of YSI 2900D Compared with YSI 2300 STAT Plus for Glucose Concentration Measurements.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-901-P
- By:
- Publication type:
- Article
23
107-LB: Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects (HS).
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-107-LB
- By:
- Publication type:
- Article
24
106-LB: Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Subjects with T1DM and T2DM.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-106-LB
- By:
- Publication type:
- Article
25
982-P: A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-982-P
- By:
- Publication type:
- Article
26
53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-53-OR
- By:
- Publication type:
- Article
27
1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1023-P
- By:
- Publication type:
- Article
28
1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1014-P
- By:
- Publication type:
- Article
29
1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1001-P
- By:
- Publication type:
- Article
30
Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes.
- Published in:
- Current Medical Research & Opinion, 2009, v. 25, n. 11, p. 2679, doi. 10.1185/03007990903223739
- By:
- Publication type:
- Article
31
Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action 每日1次给予德谷胰岛素(一种持续作用时间超长的基础胰岛素)治疗后在2-3日内可以达到稳态
- Published in:
- Journal of Diabetes, 2016, v. 8, n. 1, p. 132, doi. 10.1111/1753-0407.12266
- By:
- Publication type:
- Article
32
A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 6, p. 1383, doi. 10.1002/cpt.3225
- By:
- Publication type:
- Article
33
A Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Insulin Dimer.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 1, p. 125, doi. 10.1002/cpt.2607
- By:
- Publication type:
- Article
34
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01788-6
- By:
- Publication type:
- Article
35
Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH.
- Published in:
- Endocrinology, Diabetes & Metabolism, 2022, v. 5, n. 3, p. 1, doi. 10.1002/edm2.335
- By:
- Publication type:
- Article
36
Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients.
- Published in:
- Endocrinology, Diabetes & Metabolism, 2021, v. 4, n. 2, p. 1, doi. 10.1002/edm2.217
- By:
- Publication type:
- Article
37
Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2025, v. 61, n. 9, p. 1467, doi. 10.1111/apt.70020
- By:
- Publication type:
- Article
38
Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes.
- Published in:
- PLoS ONE, 2014, v. 9, n. 8, p. 1, doi. 10.1371/journal.pone.0105638
- By:
- Publication type:
- Article
39
Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long‐acting glucagon analogue HM15136 in overweight and obese patients with co‐morbidities.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 9, p. 2723, doi. 10.1111/dom.15162
- By:
- Publication type:
- Article
40
Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready‐to‐use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2679, doi. 10.1111/dom.14520
- By:
- Publication type:
- Article
41
Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 3, p. 700, doi. 10.1111/dom.14272
- By:
- Publication type:
- Article
42
Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 8, p. 1292, doi. 10.1111/dom.14032
- By:
- Publication type:
- Article
43
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 11, p. 2429, doi. 10.1111/dom.13824
- By:
- Publication type:
- Article
44
Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK‐1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 2, p. 400, doi. 10.1111/dom.13084
- By:
- Publication type:
- Article
45
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 1, p. 94, doi. 10.1111/dom.13042
- By:
- Publication type:
- Article
46
<sup>LAPS</sup>Insulin115: A novel ultra-long-acting basal insulin with a unique action profile.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 12, p. 1722, doi. 10.1111/dom.13006
- By:
- Publication type:
- Article
47
Endocrine Homeostasis with Inhibition of Tissue-Specific Cortisone Reductase Activity in Healthy Volunteers and Obese Insulin Resistant Subjects Following Oral INCB13739 11βHSD1 Inhibitor Therapy.
- Published in:
- Diabetes, 2007, v. 56, p. A572
- By:
- Publication type:
- Article
48
Pharmacokinetics and Pharmacodynamics of Insulin VIAject™ and Regular Human Insulin When Injected Subcutaneously Directly Before a Meal in Patients with Type I Diabetes.
- Published in:
- Diabetes, 2007, v. 56, p. A9
- By:
- Publication type:
- Article